NASDAQ
UTMD
Last Price
US $71.00
KEY FIGURES
MKT CAP
$226.1M
EPS
TTM
$3.29
PEG
TTM
N/M
P/E
TTM
21.56x
P/S
TTM
6.26x
YIELD
1.74%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
8.74%
Return on equity
ROIC: 6.83%
Valuation History
22.1X
Price to Earnings
EV/EBITDA: 15.4X
Cash flow
Profit margin
-1.80%
(FY vs FY)
EBITDA Y/Y
-3.99%
(FY vs FY)
Cash flow Y/Y
-5.77%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $71.00
-5.10%
Default assumptions
EBITDA Multiple
Fair Value
Market $71.00
-9.89%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Utah Medical Products, Inc. cash flow to debt ratio of 6.53K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial risk - Healthy cash flow growth.
Utah Medical Products, Inc.'s free cash flow has decreased -1.88% from $14.60M last year to $14.32M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Utah Medical Products, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Utah Medical Products, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Utah Medical Products, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial risk - ICR.
Interest expense is not separately reported in Utah Medical Products, Inc.'s latest filing, so interest coverage cannot be calculated.
Financial risk - Profit margin growth.
Utah Medical Products, Inc.'s profit margin has decreased (-14.38%) in the last year from 33.92% to 29.04%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Utah Medical Products, Inc.'s short-term assets of $97.74M exceed its short-term liabilities of $2.60M
Increasing performance - ROA.
Utah Medical Products, Inc.'s return on assets of 8.42% is higher than the 5.00% threshold, indicating efficient asset utilization
Decreasing performance - Absolute return on equity.
Utah Medical Products, Inc.'s return on equity of 8.74%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Utah Medical Products, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Utah Medical Products, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Utah Medical Products, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Utah Medical Products, Inc. has a free cash flow yield of 6.33%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Decreasing performance - Healthy earnings growth.
Utah Medical Products, Inc.'s yearly earnings has decreased -18.65% since last year from $13.87M to $11.29M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Utah Medical Products, Inc.'s yearly revenue has decreased -5.83% since last year from $40.90M to $38.52M, signaling decreasing performance
Increasing performance - ROIC.
ROIC 6.83% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Decreasing performance - 3-year revenue CAGR.
Utah Medical Products, Inc.'s 3-year revenue CAGR of -9.68% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Utah Medical Products, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Increasing performance - ROE consistency.
Utah Medical Products, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Utah Medical Products, Inc. is overvalued relative to its fair value price of 67.38 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Utah Medical Products, Inc. has an earnings yield of 4.64%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Utah Medical Products, Inc. is overvalued relative to its fair value price of 63.98 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Utah Medical Products, Inc. has an EV/EBITDA ratio of 8.24x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Utah Medical Products, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.
Undervalued - P/B ratio.
Utah Medical Products, Inc. has a price-to-book ratio of 1.85x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Utah Medical Products, Inc. has a price-to-sales ratio of 6.26x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue